Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma
Brief Summary: RATIONALE: Drugs used in chemotherapy such as doxorubicin and ifosfamide use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors, such as pegfilgrastim, cause the body to make blood cells. It is not yet known whether doxorubicin alone is more effective with or without ifosfamide and pegfilgrastim in treating soft tissue sarcoma.

PURPOSE: This randomized phase III trial is studying giving doxorubicin alone to see how well it works compared to giving doxorubicin together with ifosfamide and pegfilgrastim in treating patients with locally advanced or metastatic soft tissue sarcoma.


Options:
A: Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: isolated perfusion; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
B: Intervention Type: BIOLOGICAL; Name: pegfilgrastim; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: multimodality therapy; Assigned to Arm(s): N/A
C: Arm Label: sorafenib and everolimus; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib, Drug: Everolimus | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): sorafenib and everolimus | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): sorafenib and everolimus
D: Arm Label: Arm I (Patients off-therapy before callback-Induction only); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm II (RER with CR [ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm III (RER with CR [ABVE-PC]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm IV (RER with less than CR [ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm V (RER with PD); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm VI (SER [DECA, ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cisplatin, Drug: Cyclophosphamide, Drug: Cytarabine, Drug: Dexamethasone, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm VII (SER [ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Intervention Type: BIOLOGICAL; Name: Bleomycin Sulfate; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Arm VI (SER [DECA, ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): Arm VI (SER [DECA, ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Arm VI (SER [DECA, ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Doxorubicin Hydrochloride; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: BIOLOGICAL; Name: Filgrastim; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: RADIATION; Name: Involved-Field Radiation Therapy; Assigned to Arm(s): Arm II (RER with CR [ABVE-PC, IFRT]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Vincristine Sulfate Liposome; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT])

Answer: B